Corrigendum to "Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II"

Affiliations

• ¹ University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: muenzer@med.unc.edu.
• ² Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University, Chicago, IL, USA.
• ³ UCSF Benioff Children's Hospital Oakland, Oakland, CA, USA.
• ⁴ Infant Jesus Children's Hospital, Madrid, Spain.
• ⁵ National Institute of Pediatrics, Mexico City, Mexico.
• ⁶ St Mary's Hospital, Manchester University NHS Foundation Trust, University of Manchester, Manchester, UK.
• ⁷ Reference Center for Inherited Metabolic Diseases, Hospices Civils de Lyon, Lyon, France.
• ⁸ University of Toronto, Toronto, ON, Canada; The Hospital for Sick Children, Toronto, ON, Canada.
• ⁹ Women's and Children's Hospital, North Adelaide, SA, Australia.
• ¹⁰ Takeda Development Center Americas, Inc., Cambridge, MA, USA; Hale Scientific Statistics, LLC, Beaverton, OR, USA.
• ¹¹ Takeda Development Center Americas, Inc., Lexington, MA, USA.
• ¹² Takeda Development Center Americas, Inc., Cambridge, MA, USA.
• ¹³ Takeda Development Center Americas, Inc., Lexington, MA, USA; Affinia Therapeutics, Inc., Waltham, MA, USA.